European Sepsis Care Survey
Sponsor: Becton, Dickinson and Company
Listed as NCT05059808, this observational or N/A phase trial focuses on Sepsis and remains completed. Sponsored by Becton, Dickinson and Company, it has been updated 9 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2023 — Jul 2024 [monthly]
Completed
Status: Enrolling By Invitation → Completed
-
Feb 2023 — Jul 2023 [monthly]
Enrolling By Invitation
▶ Show 4 earlier versions
-
Jun 2022 — Feb 2023 [monthly]
Enrolling By Invitation
-
Mar 2022 — Jun 2022 [monthly]
Enrolling By Invitation
-
Nov 2021 — Mar 2022 [monthly]
Enrolling By Invitation
-
Oct 2021 — Nov 2021 [monthly]
Enrolling By Invitation
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Becton, Dickinson and Company
- European Sepsis Alliance
- European Shock Society
- European Society for Emergency Medicine (EUSEM) Research Network
- European Society of Anaesthesiology and Intensive Care
- European Society of Clinical Microbiology and Infectious Diseases, ESGBIES Study Group
- European Society of Intensive Care Medicine
- Sepsisdialog, Germany
- University Medicine Greifswald
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Athens, Greece , Bucharest, Romania , Chisinau, Moldova , Edegem, Belgium , Garches, France , Greifswald, Germany , Groningen, Netherlands , Helsinki, Finland , London, United Kingdom and 10 more locations